NCT02332811View on ClinicalTrials.gov

An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Renal Failure Chronic
Interventions
DRUG

sevelamer carbonate 800mg

"Pharmaceutical form:tablet~Route of administration: oral"

DRUG

sevelamer carbonate 2.4 g

"Pharmaceutical form:powder~Route of administration: oral"

Trial Locations (1)

Unknown

Russia, Moscow

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT02332811 - An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD Patients | Biotech Hunter | Biotech Hunter